Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
6B11-OCIK in recurrent drug-resistant ovarian cancer
NCT03542669Phase 1Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Aug 2018
- Primary completion
- Dec 2022
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, open-label trial of 6B11-OCIK in ovarian cancer, sponsored by Peking University People's Hospital. Primary endpoint: Maximum Tolerable Dose at 1 year. Status: unknown.
02
Drugs
6B11-OCIK
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03542669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03542669.